Thieves make away with almost 200 iPhone 5s just before they go on sale
(Reuters) - Cancer drugmaker Astex Pharmaceuticals Inc said it would discontinue the development of its experimental small-cell lung cancer drug, Amuvatinib, as the drug failed to achieve a high enough response rate in patients in a mid-stage study. Shares of the company were down about 10 percent at $3 in premarket trade. They closed at $3.32 on Thursday on the Nasdaq. The main goal of the trial, known as ESCAPE, was to show that the drug had a response rate of not less than 10 percent in treating lung cancer patients. Amuvatinib fell short with a 9.5 percent response rate. ...
sugar cookie recipe sugar cookie recipe how the grinch stole christmas macaroni and cheese festivus festivus zeno